REDWOOD CITY, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- biotricity inc. (OTC.QB:BTCY), a healthcare technology company committed to delivering innovative, medically relevant biometric remote monitoring solutions, has partnered with Global to Local (G2L), an organization dedicated to providing programs that improve individual and community health outcomes, expand access to healthcare services, and empower economic development in the most diverse and underserved communities. The collaboration between biotricity and G2L will initially focus on building innovative solutions for outcome measurements for individuals suffering from chronic disease. ?
?“Underserved populations face barriers to basic health and economic resources, including a lack of access to preventative care, which contributes to the mismanagement of chronic disease and can result in a shortened lifespan,” said Dr. Siddiqui, Director of Research and Innovation at Global to Local.
G2L has tested numerous chronic disease management solutions on the market – and to date, have not found any that address the needs of the patient, the needs of the provider, and needs of the health system in a way that creates efficiency and drives down costs. “We are excited to work closely with biotricity and translate our expertise to help them build solutions that can be scaled efficiently and work effectively for everyone involved,” Siddiqui added.
This partnership with biotricity enables G2L to apply its clinical expertise to help develop the next generation of chronic care solutions that address the gaps identified in existing solutions. biotricity’s expertise in remote monitoring technology is a perfect fit with G2L’s goal of using innovative, holistic, and community-driven solutions to address health and economic disparities in various low-income populations.
Global to Local’s approach recognizes that access to good health is dependent on factors such as economic opportunity, education, language, and job skills.? G2L is piloting global approaches to improve individual and community health outcomes for prediabetes, diabetes, and obesity with a focus on improving access through low-cost solutions while also empowering economic development in two of the most diverse and underserved communities in King County, Washington – SeaTac and Tukwila. ?Their long-term goal is to design a sustainable model of care for communities around the country that face similar health and economic disparities. G2L’s programs have already expanded into other parts of Washington State, and will soon enter nearby states through their partnerships with Providence Health, Swedish Hospital, and Washington State University.
“Our partnership with G2L is an important step for us, as we develop a solution for the chronic care markets they serve,” said Waqaas Al-Siddiq, biotricity founder and CEO. Affiliating with an organization like G2L gives biotricity multiple benefits such as identifying current gaps within existing solutions, a deeper understanding of all stakeholders, and the ability to pilot its solutions.
“As we move beyond the cardiac market?, we will utilize G2L’s diabetes and care management expertise to build a chronic care management platform for diabetes and other chronic illnesses,” added Al-Siddiq.
biotricity’s mission is to develop multiple solutions for chronic illnesses by designing monitoring devices paired with chronic care management tools to improve patient compliance and empower the individual to take better care of their health. The Company’s next generation medical-grade wearables will pave the way for the adoption of preventive care measures into mainstream healthcare practices. It will shift the current “reactive” model - where physicians diagnose and treat conditions and diseases after onset - to proactive. This is particularly true of managing heart-related illnesses, as patients often fail to comply with their doctor's medical directives, dietary changes, exercise regiments, and lifestyle alterations, without any feedback mechanism or continuous monitoring. biotricity has developed solutions that will initially work within the cardiac market as cardiovascular disease is the number one killer.
About Global To Local
Founded in 2010 through a partnership of Swedish Health Services, HealthPoint, Public Health Seattle & King County, and the Washington Global Health Alliance, along with the Cities of SeaTac and Tukwila, their demonstrate the effectiveness of global health strategies, techniques, methodologies, and technologies to improve the health status of underserved local communities with the goal of sharing learnings and scaling successes. Programs focus on drawing upon innovative, holistic and community-driven solutions to address health and economic development disparities in diverse, low-income populations. To learn more, visit www.globaltolocal.org.
About biotricity, Inc.
biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Media Contacts McCoin & Smith Communications Inc. Chris McCoin, Chris@mccoinsmith.com, 508-429-5988 Richard Smith, firstname.lastname@example.org, 978-433-3304 Investor Relations: Michael Koehler Liolios Group, Inc. BTCY@liolios.com 949-574-3860